Citius Pharmaceuticals Inc
CTXR
查看详细走势图
1.070USD
+0.050+4.90%
收盘 12/19, 16:00（美东）报价延迟15分钟
15.49M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.90%
5天
-4.46%
1月
+8.08%
6月
-0.93%
今年开始到现在
-73.25%
1年
-58.85%
查看详细走势图
TradingKey Citius Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Citius Pharmaceuticals Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名206/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.00。中期看，股价处于平稳状态。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Citius Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
5.000
目标均价
+346.43%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Citius Pharmaceuticals Inc亮点
亮点风险
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值-0.01，处于3年历史高位
机构加仓
最新机构持股2.08M股，环比增加41.27%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值166.39K
Citius Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Citius Pharmaceuticals Inc简介
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
公司代码CTXR
公司Citius Pharmaceuticals Inc
CEOMazur (Leonard L)
网址https://www.citiuspharma.com/
常见问题
Citius Pharmaceuticals Inc(CTXR)的当前股价是多少？
Citius Pharmaceuticals Inc(CTXR)的当前股价是 1.070。
Citius Pharmaceuticals Inc的股票代码是什么？
Citius Pharmaceuticals Inc的股票代码是CTXR。
Citius Pharmaceuticals Inc股票的52周最高点是多少？
Citius Pharmaceuticals Inc股票的52周最高点是5.950。
Citius Pharmaceuticals Inc股票的52周最低点是多少？
Citius Pharmaceuticals Inc股票的52周最低点是0.650。
Citius Pharmaceuticals Inc的市值是多少？
Citius Pharmaceuticals Inc的市值是15.49M。
Citius Pharmaceuticals Inc的净利润是多少？
Citius Pharmaceuticals Inc的净利润为-40.19M。
现在Citius Pharmaceuticals Inc(CTXR)的股票是买入、持有还是卖出？
根据分析师评级，Citius Pharmaceuticals Inc(CTXR)的总体评级为买入，目标价格为5.000。
Citius Pharmaceuticals Inc(CTXR)股票的每股收益（EPS TTM）是多少
Citius Pharmaceuticals Inc(CTXR)股票的每股收益（EPS TTM）是-148.242。
相关品种
